Pages that link to "Q415271"
Jump to navigation
Jump to search
The following pages link to Erb-b2 receptor tyrosine kinase 2 (Q415271):
Displaying 50 items.
- lapatinib (Q420323) (← links)
- pertuzumab (Q1998021) (← links)
- afatinib (Q4688818) (← links)
- canertinib (Q5032274) (← links)
- mubritinib (Q6930896) (← links)
- neratinib (Q6995920) (← links)
- ERBB2 (Q14877486) (← links)
- dacomitinib (Q17130597) (← links)
- (Q21104731) (redirect page) (← links)
- Update on HER-2 as a target for cancer therapy: intracellular signaling pathways of ErbB2/HER-2 and family members (Q21195197) (← links)
- Copine-III interacts with ErbB2 and promotes tumor cell migration (Q22001536) (← links)
- Dominance of ErbB-1 heterodimers in lung epithelial cells overexpressing ErbB-2. Both ErbB-1 and ErbB-2 contribute significantly to tumorigenicity (Q22010838) (← links)
- Interaction between protein tyrosine phosphatase and protein tyrosine kinase is involved in androgen-promoted growth of human prostate cancer cells (Q22254244) (← links)
- Identification of a region within the ErbB2/HER2 intracellular domain that is necessary for ligand-independent association (Q24297029) (← links)
- HER2 kinase domain mutation results in constitutive phosphorylation and activation of HER2 and EGFR and resistance to EGFR tyrosine kinase inhibitors (Q24297102) (← links)
- Endosomal transport of ErbB-2: mechanism for nuclear entry of the cell surface receptor (Q24297204) (← links)
- Segregation of receptor and ligand regulates activation of epithelial growth factor receptor (Q24298164) (← links)
- Comparative analysis of fluorescence resonance energy transfer (FRET) and proximity ligation assay (PLA) (Q24299425) (← links)
- Nuclear ErbB2 enhances translation and cell growth by activating transcription of ribosomal RNA genes (Q24301779) (← links)
- ErbB2 receptor controls microtubule capture by recruiting ACF7 to the plasma membrane of migrating cells (Q24302369) (← links)
- Transforming growth factor {beta} (TGF-{beta})-Smad target gene protein tyrosine phosphatase receptor type kappa is required for TGF-{beta} function (Q24302428) (← links)
- Coexpression of erbB2 and erbB3 proteins reconstitutes a high affinity receptor for heregulin (Q24305421) (← links)
- Heregulin-dependent regulation of HER2/neu oncogenic signaling by heterodimerization with HER3 (Q24309266) (← links)
- IQGAP1 protein binds human epidermal growth factor receptor 2 (HER2) and modulates trastuzumab resistance (Q24309891) (← links)
- Tid1, the human homologue of a Drosophila tumor suppressor, reduces the malignant activity of ErbB-2 in carcinoma cells (Q24310497) (← links)
- ErbB2-mediated Src and signal transducer and activator of transcription 3 activation leads to transcriptional up-regulation of p21Cip1 and chemoresistance in breast cancer cells (Q24316918) (← links)
- Requirement of ErbB2 for signalling by interleukin-6 in prostate carcinoma cells (Q24317507) (← links)
- Reciprocal regulation of neu tyrosine kinase activity and caveolin-1 protein expression in vitro and in vivo. Implications for human breast cancer (Q24318999) (← links)
- Flow cytometric in situ proximity ligation analyses of protein interactions and post-translational modification of the epidermal growth factor receptor family (Q24319831) (← links)
- Parallel visualization of multiple protein complexes in individual cells in tumor tissue (Q24320208) (← links)
- Identification and validation of novel ERBB2 (HER2, NEU) targets including genes involved in angiogenesis (Q24323685) (← links)
- The tumor suppressor RECK interferes with HER-2/Neu dimerization and attenuates its oncogenic signaling (Q24337918) (← links)
- Identification of heregulin, a specific activator of p185erbB2 (Q24338146) (← links)
- Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab (Q24600031) (← links)
- Regulation of ERBB2 by oestrogen receptor-PAX2 determines response to tamoxifen (Q24632895) (← links)
- Common ERBB2 polymorphisms and risk of breast cancer in a white British population: a case-control study (Q24797594) (← links)
- Update on HER-2 as a target for cancer therapy: herceptin in the clinical setting (Q24801924) (← links)
- Update on HER-2 as a target for cancer therapy: the ERBB2 promoter and its exploitation for cancer treatment (Q24801967) (← links)
- Update on HER-2 as a target for cancer therapy: HER2/neu peptides as tumour vaccines for T cell recognition (Q24801995) (← links)
- A new model for ductal carcinoma in situ suggests strategies for treatment (Q24802734) (← links)
- Tyrosine kinase signalling in breast cancer: ErbB family receptor tyrosine kinases (Q24802950) (← links)
- ERBB2 in cat mammary neoplasias disclosed a positive correlation between RNA and protein low expression levels: a model for erbB-2 negative human breast cancer (Q24810389) (← links)
- Immunohistochemical evaluation of human epidermal growth factor receptor 2 and estrogen and progesterone receptors in breast carcinoma in Jordan (Q24813346) (← links)
- tucatinib (Q25100690) (← links)
- First-line therapy in HER2 positive metastatic breast cancer: is the mosaic fully completed or are we missing additional pieces? (Q26746081) (← links)
- Retargeting Strategies for Oncolytic Herpes Simplex Viruses (Q26765439) (← links)
- Breast cancer survival among young women: a review of the role of modifiable lifestyle factors (Q26766205) (← links)
- Genomic classification of lung cancer: toward a personalized treatment (Q26773815) (← links)
- HER2 Status in Premalignant, Early, and Advanced Neoplastic Lesions of the Stomach (Q26780318) (← links)
- Serum HER2 Is a Potential Surrogate for Tissue HER2 Status in Gastric Cancer: A Systematic Review and Meta-Analysis (Q26796280) (← links)